BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29166452)

  • 21. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.
    Prestwich RJ; Viner S; Gerrard G; Patel CN; Scarsbrook AF
    Br J Radiol; 2012 Oct; 85(1018):e805-13. PubMed ID: 22972977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ¹⁸F-FDG-PET and ¹⁸F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis.
    Cheng X; Bao L; Xu Z; Li D; Wang J; Li Y
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):136-42. PubMed ID: 22498184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG avid supraclavicular neck adenopathy of tubercular etiology masquerading as neck recurrence in differentiated thyroid carcinoma: potential source of false positive FDG-PET study.
    Basu S; Menon S
    Int J Oral Maxillofac Surg; 2010 Jun; 39(6):628-9. PubMed ID: 20194002
    [No Abstract]   [Full Text] [Related]  

  • 27. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Fu H; Fu J; Huang J; Pang Y; Chen H
    Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
    Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
    Treglia G; Castaldi P; Villani MF; Perotti G; Filice A; Ambrosini V; Cremonini N; Versari A; Fanti S; Giordano A; Rufini V
    Recent Results Cancer Res; 2013; 194():385-93. PubMed ID: 22918771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
    Haslerud T; Brauckhoff K; Reisæter L; Küfner Lein R; Heinecke A; Varhaug JE; Biermann M
    Acta Radiol; 2016 Oct; 57(10):1193-200. PubMed ID: 26163534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of thyroid, head, and neck cancers with PET.
    Zhuang H; Kumar R; Mandel S; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1101-11, viii. PubMed ID: 15488560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms.
    Lang BH; Law TT
    Oncologist; 2011; 16(4):458-66. PubMed ID: 21378078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.